2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clinical Cancer Research 2022, 28: 3752-3760. PMID: 35713632, PMCID: PMC9444942, DOI: 10.1158/1078-0432.ccr-22-0741.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalEGFR mutationsNon-small cell lung cancerCycle 3 day 1Median progression-free survivalMedian overall survivalRisk of progressionCell lung cancerPresence of brainEGFR-mutant NSCLCBaseline ctDNAM1b stageProgression-FreeRECIST responseSerial plasmaLiver metastasesDecreased riskEGFR-TKILung cancerComplete clearanceLong-term benefitsClinical trialsTreatment outcomesPlasma clearance
2017
A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease
Stahl JM, Walther Z, Chang BW, Hochster HS, Johung KL. A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease. Cureus 2017, 9: e1007. PMID: 28293485, PMCID: PMC5333949, DOI: 10.7759/cureus.1007.Peer-Reviewed Case Reports and Technical NotesPancreatic ductal adenocarcinomaOligometastatic pancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaAdjuvant gemcitabineResectable pancreatic ductal adenocarcinomaAggressive local therapyRecurrence 12 yearsMultiple liver metastasesAggressive local treatmentMetastatic pancreatic adenocarcinomaLong-term survivorsIdentification of patientsMutations of KRASSmall lung nodulesTime of deathTumor protein p53Oligometastatic diseaseDistant progressionLiver metastasesMetastatic diseaseDisease recurrenceLocal therapyWhipple procedureComplete resolutionAnastomosis site